Connection
Tyler Robin to Prostatic Neoplasms
This is a "connection" page, showing publications Tyler Robin has written about Prostatic Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.877 |
|
|
|
-
Robin TP, Geiger CL, Callihan EB, Kessler ER. Prostate Cancer in Older Adults: Risk of Clinically Meaningful Disease, the Role of Screening and Special Considerations. Curr Oncol Rep. 2021 08 27; 23(11):130.
Score: 0.409
-
Robin TP, Maroni PD, Chin BB, La Rosa FG, Bernard B, Pugh TJ. Post-Prostatectomy Radiation Therapy: Patient Selection, Timing, Imaging, and Therapy Intensification. Oncology (Williston Park). 2018 07 15; 32(7):360-3, 369, CV3.
Score: 0.329
-
Spratt DE, Srinivas S, Adra N, Ahmed B, An Y, Bitting R, Chapin B, Cheng HH, Cho SY, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Ippolito JE, Karnes RJ, Kishan AU, Kuettel MR, Lang JM, Lee D, Lotan T, McDonald A, Morgan TM, Pessoa R, Rais-Bahrami S, Roach M, Robin T, Rosenfeld S, Scarpato KR, Seibert T, Shabsigh A, Szmulewitz R, Teply BA, Tward J, Valicenti R, VanderWeele D, Wong JK, Kovach E, Freedman-Cass D. NCCN GuidelinesĀ® Insights: Prostate Cancer, Version 5.2026. J Natl Compr Canc Netw. 2026 May; 24(5):140-149.
Score: 0.141
-
Spratt DE, Srinivas S, Adra N, Ahmed B, An Y, Bitting R, Chapin B, Cheng HH, Cho SY, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Ippolito JE, Karnes RJ, Kishan A, Kuettel MR, Lang JM, Lee D, Lotan T, McDonald A, Morgan T, Pessoa R, Rais-Bahrami S, Roach M, Robin T, Rosenfeld S, Scarpato KR, Shabsigh A, Szmulewitz R, Teply BA, Tward J, Valicenti R, VanderWeele D, Wong JK, Kovach E, Freedman-Cass D. Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 11; 23(11):469-493.
Score: 0.137
-
Patel SA, Kollmeier M, Crook J, Krauss D, Morton G, Chang AJ, Helou J, Hsu IC, Menard C, Patel S, Robin T, Rossi PJ, Zelefsky MJ, Kamrava MR. High-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy for localized prostate cancer: An evidence-based consensus statement. Brachytherapy. 2025 Sep-Oct; 24(5):644-662.
Score: 0.134
-
Eule CJ, Warren A, Molina Kuna E, Robin TP, Gershman B, Kim SP, Flaig TW. Clinical characteristics and treatment of patients with small cell prostate cancer: analysis of a real-world cohort from an oncology database. Prostate Cancer Prostatic Dis. 2025 Jun; 28(2):444-450.
Score: 0.128
-
Eule CJ, Kuna EM, Robin TP, Gershman B, Flaig TW, Kim SP. Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of Real-World Practice Patterns from the CancerLinQ Database. Urol Oncol. 2024 12; 42(12):447.e17-447.e24.
Score: 0.126
-
Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Karnes RJ, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Szmulewitz R, Teply BA, Tward J, Valicenti R, Wong JK, Snedeker J, Freedman-Cass DA. NCCN GuidelinesĀ® Insights: Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 04; 22(3):140-150.
Score: 0.122
-
Mak KS, Scannell Bryan M, Dignam JJ, Shipley WU, Lin Y, Peters CA, Gore EM, Rosenthal SA, Zeitzer KL, D'Souza DP, Horwitz EM, Pisansky TM, Maier JM, Chafe SM, Robin TP, Roach M, Tran PT, Souhami L, Michalski JM, Hartford AC, Feng FY, Sandler HM, Efstathiou JA. Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202. Eur Urol Focus. 2024 03; 10(2):271-278.
Score: 0.121
-
Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Shead DA, Snedeker J, Freedman-Cass DA. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 10; 21(10):1067-1096.
Score: 0.118
-
Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA, Freedman-Cass DA. NCCN GuidelinesĀ® Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Netw. 2022 12; 20(12):1288-1298.
Score: 0.112
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|